GT Biopharma Inc (GTBP)
3.12
-0.15
(-4.59%)
USD |
NASDAQ |
May 17, 16:00
3.83
+0.71
(+22.76%)
After-Hours: 20:00
GT Biopharma Research and Development Expense (Annual): 6.466M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 6.466M |
| December 31, 2022 | 8.811M |
| December 31, 2021 | 9.591M |
| December 31, 2020 | 0.485M |
| December 31, 2019 | 1.667M |
| December 31, 2018 | 9.067M |
| December 31, 2017 | 1.068M |
| December 31, 2016 | 0.975M |
| December 31, 2015 | 1.00M |
| December 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| December 31, 2012 | 0.00 |
| December 31, 2011 | 0.017M |
| December 31, 2010 | 0.179M |
| December 31, 2009 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2008 | 0.044M |
| December 31, 2007 | 1.037M |
| December 31, 2006 | 0.708M |
| December 31, 2005 | 0.499M |
| December 31, 2004 | 0.278M |
| December 31, 2003 | 0.369M |
| December 31, 2002 | 0.463M |
| December 31, 2001 | 0.762M |
| December 31, 2000 | 1.91M |
| December 31, 1999 | 2.401M |
| December 31, 1998 | 4.40M |
| December 31, 1997 | 4.30M |
| December 31, 1996 | |
| December 31, 1995 | 4.30M |
| December 31, 1994 | 1.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
0.485M
Minimum
2020
9.591M
Maximum
2021
5.404M
Average
6.466M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Cutera Inc | 21.41M |
| Outlook Therapeutics Inc | 26.45M |
| 180 Life Sciences Corp | 2.784M |
| Journey Medical Corp | 7.541M |
| NovaBay Pharmaceuticals Inc | 0.068M |